Skip to main content
. Author manuscript; available in PMC: 2021 Nov 23.
Published in final edited form as: Sci Transl Med. 2021 Mar 3;13(583):eabc8980. doi: 10.1126/scitranslmed.abc8980

Figure 4. C-peptide over time in the two treatment arms over the first year.

Figure 4.

The log-transformed mean C-peptide AUC is shown. Arrows indicate individual drop out from OGTT monitoring due to diabetes development at each timepoint. Median value for “pre-baseline” timepoint was 24. Months prior to randomization and median value for “baseline” timepoint was 0.85 months prior to randomization. *P<0.05 for comparisons of 6-month on-treatment C-peptide AUC values to baseline in the teplizumab group and 6-month C-peptide AUC values in the teplizumab group to 6-month C-peptide AUC values in the placebo group.